Smiths Detection completes acquisition of PathSensors

▴ Smiths Detection completes acquisition of PathSensors
Smith Detection takes over Pathsensors to keep ahead in the COVID challenge

Smiths Detection, a global leader in detection and screening technologies, today confirmed that it has completed the acquisition of PathSensors, leading biotechnology solutions and environmental-testing company, based in Baltimore, MD, USA.

The acquisition strengthens Smiths Detection’s biological-detection capabilities to detect pathogens for broad end-market applications, including in food and agriculture safety.


“We are pleased to be able to complete this acquisition, which we view as a significant strategic step in accelerating how we are able to respond to biological threats, which are becoming increasingly relevant in the current environment,” said Roland Carter, President Smiths Detection. “PathSensors has developed such a capability – with its multiple threat assays already available, it is able to identify biological threats in minutes and will provide a suitable biological capability to our customers.”Smiths Detection, part of Smiths Group, is a global leader in threat detection and screening technologies for aviation, ports and borders, defense and urban security markets. Our experience and history across more than 40 years at the frontline, enables us to deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics. 

PathSensors is a leading biotechnology solution and environmental testing company providing high-speed, high-sensitivity pathogen detection and threat prevention solutions. PathSensors’ solutions can detect a wide range of threats, including anthrax, ricin, Ebola, Salmonella, Phytophthora, Ralstonia, and many more.

Recently Smiths Detection also announced that it has collaborated with Attomarker Ltd, a multiplex blood-testing technology company spun out of the University of Exeter, to help produce a robust and accurate COVID-19 antibody-testing device that could represent an evolution in rapid and precise COVID-19 antibody testing. The Medicines and Healthcare Products Regulatory Agency (MHRA) has already approved Attomarker’s Triple Antibody Test for NHS use in the UK.

The Smiths Detection team has been working alongside Attomarker since April on the design and performance of the device and has manufactured 10 pre-production units, with the ability to ramp up volume according to demand.

Attomarker’s Triple Antibody Test device is a portable, desktop, antibody-testing device designed to provide laboratory-standard results in any environment. It delivers rapid, accurate, quantitative results in just seven minutes – compared with up to 72 hours for tests that require to be sent away for laboratory analysis.

The result of a trial at St Thomas’ Hospital in London – published this week in the Royal Society of Chemistry’s journal Analyst – shows that the Attomarker Triple Antibody Test delivers a sensitivity of up to 96% in detecting COVID-19 antibodies, including in patients who have previously presented false negatives.1 This is a significant improvement on recently announced tests, which range between 83.9% – 93.9% – though not with real-world patients.2,3

A developer and manufacturer of leading-edge threat-detection equipment for security industries, Smiths Detection frequently partners with companies and governments to develop equipment that is both highly accurate in the detection and offers the highest standard of technical performance.

Commenting on Smiths Detection’s involvement in the project, Smiths Detection President Roland Carter said: “The Smiths Detection team was able to take the current designs of the existing product and make enhancements that will contribute not only to its improved performance and robustness but also the ease at which it can be produced.

“The success we have seen so far in this project is a testament to the high-standard research that the team is able to achieve, but also its agility and flexibility to pick up a project and deliver results. Not just from the perspective of our engineers and scientists, but also in terms of the supply chain, manufacturing and quality.”

Tags : #SmithDetection #Pathsensors #AttomarkerLtd #CovidDetection #Ebola #Salmonella #PharmaNewsUpdateAug5 #LatestPharmaNewsAug5 #SmithdetectionNewsIndia

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Lupin Launches Lapatinib TabletsSeptember 30, 2020
Ajinomoto Bio-Pharma Services and DNDi Partner to develop Critical Immunomodulator September 30, 2020
Lupin launches Lapatinib Tablets secures FDA approvalSeptember 30, 2020
Synthetic Biology introduces NanoSyrinxSeptember 30, 2020
Regular check-up & annual mammography are necessary to detect breast cancer earlySeptember 30, 2020
Regular use of acid influx drugs increase the risk of type-2 diabetesSeptember 30, 2020
Current pandemic introduces research culture in Ayush disciplineSeptember 30, 2020
Maharashtra govt calls for cancellation of Dandiya, Garba, other cultural programmes during ensuing Navratri, Durga PujaSeptember 30, 2020
Allotment of seats for admission in 1st year MBBS course will be done per existing policies: JIPMERSeptember 30, 2020
WHO to investigate allegations of sexual exploitation and abuse in Ebola response in the Democratic Republic of the CongoSeptember 30, 2020
South Korea puts virus curbs in place ahead of Chuseok holidaysSeptember 30, 2020
COVID-19 infection cases rising among U.S. childrenSeptember 30, 2020
India sustains steady trend of dipping %Active CasesSeptember 30, 2020
Private hospitals & diagnostic centres overcharging patients even for basic health services: Maharashtra Health MinisterSeptember 30, 2020
Centre releases COVID-19 Safe Workplace Guidelines for IndustrySeptember 30, 2020
COVID-19 recovery rate in country reaches 83.33%September 30, 2020
A special strategy has prepared by UP CM to tackle COVID-19September 29, 2020
China ropes in more countries for its COVID-19 vaccine trialsSeptember 29, 2020
Antarctica is still free of Covid-19. Can it stay that way?September 29, 2020
RDIF and Trinity Pharmaceuticals will provide COVID vaccine to NepalSeptember 29, 2020